Achim Rittmeyer
About
Achim Rittmeyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Achim Rittmeyer has authored 91 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Achim Rittmeyer's work include Lung Cancer Treatments and Mutations (58 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (22 papers). Achim Rittmeyer is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (22 papers). Achim Rittmeyer collaborates with scholars based in United States, Germany and France. Achim Rittmeyer's co-authors include Marcin Kowanetz, Alan Sandler, Marcus Ballinger, Keunchil Park, Julien Mazières, Louis Fehrenbacher, Daniel Waterkamp, Johan Vansteenkiste, Alexander I. Spira and Pei He and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Achim Rittmeyer
84 papers receiving 5.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Achim Rittmeyer United States | 26 | 4.9k | 3.5k | 1.1k | 687 | 593 | 91 | 5.7k | ||
| Mary J. Fidler United States | 22 | 5.2k 1.1× | 3.7k 1.0× | 1.1k 1.1× | 748 1.1× | 803 1.4× | 115 | 6.4k | ||
| Matthew A. Gubens United States | 30 | 3.4k 0.7× | 2.3k 0.6× | 754 0.7× | 524 0.8× | 565 1.0× | 100 | 4.3k | ||
| Piotr Serwatowski Germany | 15 | 4.0k 0.8× | 3.5k 1.0× | 760 0.7× | 626 0.9× | 1.0k 1.8× | 28 | 5.3k | ||
| Gene Grant Finley United States | 19 | 3.3k 0.7× | 2.2k 0.6× | 690 0.6× | 466 0.7× | 961 1.6× | 70 | 4.4k | ||
| Patrick M. Forde United States | 40 | 4.0k 0.8× | 2.7k 0.8× | 1.1k 1.1× | 645 0.9× | 934 1.6× | 186 | 5.7k | ||
| Manuel Cobo Spain | 30 | 3.6k 0.7× | 3.4k 1.0× | 565 0.5× | 1.1k 1.6× | 1.3k 2.3× | 219 | 5.3k | ||
| Naoyuki Nogami Japan | 30 | 5.9k 1.2× | 5.4k 1.5× | 757 0.7× | 969 1.4× | 1.4k 2.4× | 149 | 7.4k | ||
| Rosalyn A. Juergens Canada | 30 | 3.1k 0.6× | 1.9k 0.5× | 815 0.8× | 599 0.9× | 1.2k 2.0× | 125 | 4.3k | ||
| Willemijn S.M.E. Theelen Netherlands | 16 | 3.0k 0.6× | 3.3k 0.9× | 385 0.4× | 873 1.3× | 998 1.7× | 33 | 4.4k | ||
| Martin Sebastian Germany | 27 | 4.1k 0.8× | 3.3k 0.9× | 945 0.9× | 930 1.4× | 1.7k 2.9× | 117 | 5.8k |
Countries citing papers authored by Achim Rittmeyer
Since
Specialization
Citations
This map shows the geographic impact of Achim Rittmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Achim Rittmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Achim Rittmeyer more than expected).
Fields of papers citing papers by Achim Rittmeyer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Achim Rittmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Achim Rittmeyer. The network helps show where Achim Rittmeyer may publish in the future.
Co-authorship network of co-authors of Achim Rittmeyer
This figure shows the co-authorship network connecting the top 25 collaborators of Achim Rittmeyer. A scholar is included among the top collaborators of Achim Rittmeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Achim Rittmeyer. Achim Rittmeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39.
2.
Wakelee, Heather A., Nasser K. Altorki, Caicun Zhou, et al.. (2024). IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(17_suppl). LBA8035–LBA8035.
3.
Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612.
4.
Nishio, Makoto, Yi‐Long Wu, Fabrice Barlési, et al.. (2024). Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.. Journal of Clinical Oncology. 42(16_suppl). 8006–8006.
5.
Felip, Enriqueta, Nasser K. Altorki, Caicun Zhou, et al.. (2023). Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Annals of Oncology. 34(10). 907–919.
6.
Overbeck, Tobias R., Katja Schmitz, Achim Rittmeyer, et al.. (2023). NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients. Cancers. 15(11). 2966–2966.
7.
Gandara, David R., Martin Reck, Denis Moro‐Sibilot, et al.. (2021). Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. Journal for ImmunoTherapy of Cancer. 9(3). e001882–e001882.
8.
Tufman, Amanda, Jens Neumann, Farkhad Manapov, et al.. (2021). Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Lung Cancer. 160. 17–27.
9.
Chalabi, Myriam, Andrés F. Cardona, Deepti R. Nagarkar, et al.. (2020). Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology. 31(4). 525–531.
10.
Overbeck, Tobias R., Katja Schmitz, Achim Rittmeyer, et al.. (2020). Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Translational Lung Cancer Research. 9(3). 603–616.
11.
Mazières, Julien, Achim Rittmeyer, Shirish M. Gadgeel, et al.. (2020). 1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC. Annals of Oncology. 31. S821–S822.
12.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937.
13.
Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298.
14.
Gadgeel, Shirish M., Rimas V. Lukas, Jerome H. Goldschmidt, et al.. (2018). Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 128. 105–112.
15.
Gadgeel, S., Marcin Kowanetz, Wenbo Zou, et al.. (2017). Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study. Annals of Oncology. 28. v460–v461.
16.
Tufman, Amanda, Joachim von Pawel, Achim Rittmeyer, et al.. (2017). Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial. OncoTargets and Therapy. Volume 10. 1081–1089.
17.
Vansteenkiste, Johan, Els Wauters, Keunchil Park, et al.. (2017). Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion on Biological Therapy. 17(6). 781–789.
18.
Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581.
19.
Hirsch, Fred R., Ramaswamy Govindan, Zanete Zvirbule, et al.. (2014). Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC). International Journal of Radiation Oncology*Biology*Physics. 90(5). S37–S37.
20.
Rittmeyer, Achim, В. А. Горбунова, Anders Vikström, et al.. (2013). Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). Journal of Thoracic Oncology. 8(11). 1409–1416.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mary J. Fidler Breakdown of academic impact, for papers by Matthew A. Gubens Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Manuel Cobo Breakdown of academic impact, for papers by Naoyuki Nogami Breakdown of academic impact, for papers by Rosalyn A. Juergens Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Martin Sebastian